Teva Pharmaceutical Industries Ltd. has accused the US Department of Justice of showing an “unwillingness to consider alternatives that would not deeply impact Teva and the stakeholders who depend on the company,” after being charged with conspiring to fix prices, rig bids, and allocate customers for generic medicines in the US.
The Israeli giant – which became the seventh company to be charged in the DoJ’s the price-fixing investigation – is alleged to have participated in three schemes with other generic manufacturers, from
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?